The OGF-OGFr axis, a novel biological pathway, can be modulated in human triple-negative breast cancer cells to inhibit proliferation, according to research in the June 2013 issue of Experimental Biology and Medicine.
Exposure of human breast cancer cell lines to OGF in lab tests repressed growth within 24 hours. (That's fast, folks.) Treatment with low dosages of the opioid antagonist naltrexone (LDN) boosted OGF with minimal or no side effects, with potentially stronger effects than paclitaxel.
"What is exciting about our findings," said Ian S. Zagon, M.D., senior author and Distinguished University Professor at the University of Pennsylvania, "is that women with triple-negative breast cancer have few options because their tumors lack the necessary hormonal receptors. [Pat's note: I would say "different options" rather than "fewer."]
Data from these studies open new doors for treatment of this population of women." Moreover, the OGF-OGFr axis is present in all types of breast cancer cells suggesting that this pathway provides additional avenues for treatment of this commonly diagnosed cancer.
No comments:
Post a Comment